We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.25B
AUM Growth
+$165M
Cap. Flow
+$181M
Cap. Flow %
14.45%
Top 10 Hldgs %
67.15%
Holding
42
New
8
Increased
10
Reduced
5
Closed
1

Top Buys

Rank Stock Value
1
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$63.8M
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$33.1M
3
TYRA icon
Tyra Biosciences
TYRA
+$23.9M
4
VRDN icon
Viridian Therapeutics
VRDN
+$22.1M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.8M

Top Sells

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$57.4M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$7.68M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$7.37M
4
RGNX icon
Regenxbio
RGNX
+$4.18M
5
BLU
BELLUS Health Inc.
BLU
+$3.27M

Sector Composition

Rank Sector Weight
1 Healthcare 98.8%
2 Miscellaneous 1.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRCL
26
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$11.8M 0.95%
+851,638
New +$10.1M
RGNX icon
27
Regenxbio
RGNX
$619M
$9.88M 0.79%
235,809
-116,145
-33% -$4.18M
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
$9.33M 0.75%
951,814
+373,710
+65% +$2.94M
MTEM
29
DELISTED
Molecular Templates, Inc.
MTEM
$9.22M 0.74%
91,603
– –
ACRS icon
30
Aclaris Therapeutics
ACRS
$907M
$7.35M 0.59%
408,329
+37,596
+10% +$603K
SRRK icon
31
Scholar Rock
SRRK
$7.22B
$5.15M 0.41%
156,000
– –
IMVT icon
32
Immunovant
IMVT
$9.05B
$5.09M 0.41%
585,759
+331,759
+131% +$2.99M
APTX
33
DELISTED
Aptinyx Inc. Common Stock
APTX
$4.41M 0.35%
1,883,244
– –
EPZM
34
DELISTED
Epizyme, Inc
EPZM
$3.79M 0.3%
739,369
– –
ALNA
35
DELISTED
Allena Pharmaceuticals
ALNA
$3M 0.24%
3,330,373
– –
EPIX
36
DELISTED
ESSA Pharma
EPIX
$2.87M 0.23%
358,346
+41,730
+13% +$663K
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
$2.74M 0.22%
+156,807
New +$3.18M
BLU
38
DELISTED
BELLUS Health Inc.
BLU
$2.65M 0.21%
433,247
-863,496
-67% -$3.27M
GRTX
39
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.95M 0.16%
241,000
– –
FRLN
40
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$1.88M 0.15%
36,667
– –
NBRV
41
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$507K 0.04%
17,026
– –
TBIO
42
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-2,082,789
Closed -$57.4M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q3 2021 Portfolio in Review

As of Q3 2021, Frazier Management held 42 positions worth $1.25B, up 15% from $1.08B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Management deployed $181M of net new capital in Q3 2021, opening 8 new positions and adding to 10 existing holdings. Its largest new stake was Imago BioSciences, Inc. Common stock: 2,971,274 shares worth $59.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $7.68M trimmed.

  • Frazier Management's largest Q3 2021 buy was Imago BioSciences, Inc. Common stock: 2,971,274 shares worth $59.5M.
  • Frazier Management added most to Gritstone bio, Inc. Common Stock in Q3 2021, an estimated $33.1M increase.
  • Frazier Management's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $7.68M.
  • Frazier Management fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $57.4M.
  • Frazier Management's ten largest holdings make up 67% of its $1.25B portfolio in Q3 2021.
  • Frazier Management opened 8 new positions and closed 1 in Q3 2021.
  • Frazier Management's portfolio value rose 15% quarter-over-quarter to $1.25B.

Based on Frazier Management's 13F filing for Q3 2021, filed 12 Nov 2021.